7 results
To evaluate the efficacy and safety of BIBF 1120 in HCC patients without prior systemic treatment as compared to Sorafenib.
- To asses the safety and toxicity of peri-ablative sorafenib given in doses of either 200 mg or 400 mg twice daily.- To asses the effect of perioperative sorafenib on the RFA induced mobilization of endothelial progenitor cells and cytokines…
The objective of this study is to determine if patients without heart failure receiving Sevoflurane have a different myocardial ischemia-reperfusion injury and/or systemic inflammatory response than patients who do not receive Sevoflurane.
The primary objective of this trial is to determine whether different types of anaesthesia [regional versus general] given to infants undergoing inguinal hernia repair result in equivalent neurodevelopmental outcomes. Secondary objectives are to…
The main objective of this study is to assess effectiveness of the COVID-19 vaccinations, based on humoral (anti-coronavirus antibody) immunity, in GCA and PMR patients. Other objectives are assessing antigen-specific cellular (T-cell) immune…
The primary objective is to study protective antibody responses after SARS-CoV-2 vaccination in patients with pSS. Secondary objectives are monitoring of adverse events and disease activity after vaccination, studying the prognostic value of anti-…
The revised aims of the SORCE trial are:1. Does up to three years of treatment with sorafenib increase DFS compared with placebo: a comparison of Arm C vs Arm A2. If the answer to question (i) is yes, does one year of sorafenib (Arm B) increase DFS…